Ultragenyx Pharmaceutical shares plunged 47.6% to $13.89 in Thursday morning trading after its apazunersen treatment missed main and secondary goals in a late-stage Angelman syndrome trial. The failure wiped out $1.25 billion in market value. It marks the company's second consecutive late-stage trial failure, eroding investor confidence in a key growth pipeline.
Ultragenyx Drug Fails Trial
Ultragenyx shares dropped significantly after its Angelman syndrome treatment failed a late-stage trial. The drug did not meet its main cognitive goals, prompting analyst downgrades and spending cuts.
Xurve View
Insights:
Xurve View





